Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Graham Russell, Emeritus Professor of Musculoskeletal Pharmacology at NDORMS, has received the prestigious Gideon A. Rodan Excellence in Mentorship Award from the American Society for Bone and Mineral Research (ASBMR).

We are proud to congratulate Professor Graham Russell, Emeritus Professor of Musculoskeletal Pharmacology at NDORMS, on receiving the prestigious Gideon A. Rodan Excellence in Mentorship Award from the American Society for Bone and Mineral Research (ASBMR), at their annual meeting in Houston, Texas this September.

This award is given in recognition of outstanding support provided by a senior scientist who has helped promote the independent careers of young investigators in bone and mineral metabolism; it is certain that Prof Russell has and continues to encourage the careers of a vast number of successful musculoskeletal researchers.

This is the first time this award has been presented to a researcher from outside the US and is an excellent testimony to Professor Russell's achievements at NDORMS and within the field as a whole.

Similar stories

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.